This trial is testing a combination of two drugs to treat patients with solid tumors. Cediranib maleate blocks enzymes needed for cell growth, and olaparib may make the tumor more sensitive to Cediranib maleate.
1 Primary · 2 Secondary · Reporting Duration: Up to 2 years
126 Total Participants · 1 Treatment Group
Primary Treatment: Cediranib Maleate · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: